DexCom (NASDAQ:DXCM) versus Integer (NYSE:ITGR) Head to Head Comparison

DexCom (NASDAQ:DXCM) and Integer (NYSE:ITGR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Risk and Volatility

DexCom has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Integer has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Earnings & Valuation

This table compares DexCom and Integer”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.03 billion	6.36	$576.20 million	$1.80	36.52
Integer	$1.72 billion	1.51	$119.90 million	$2.39	30.86

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 2.2% of Integer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for DexCom and Integer, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1	5	19	3	2.86
Integer	0	7	4	0	2.36

DexCom presently has a consensus price target of $87.57, suggesting a potential upside of 33.21%. Integer has a consensus price target of $97.25, suggesting a potential upside of 31.87%. Given DexCom’s stronger consensus rating and higher possible upside, research analysts clearly believe DexCom is more favorable than Integer.

Profitability

This table compares DexCom and Integer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DexCom	15.96%	30.65%	10.56%
Integer	4.75%	12.84%	6.52%

Summary

DexCom beats Integer on 12 of the 15 factors compared between the two stocks.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.